Biomarker Discovery of CSF biomarker of medulloblastoma by SELDI-TOF mass spectrometry

生物标志物 通过 SELDI-TOF 质谱法发现髓母细胞瘤的 CSF 生物标志物

• 批准号: 12470293
• 负责人: TABUCHI Kazuo
• 金额: $ 8.77万
• 依托单位: Saga Medical School
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (B)
• 财政年份: 2000
• 资助国家: 日本
• 起止时间: 2000 至 2001
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/en/grant/KAKENHI-PROJECT-12470293/
• 关键词: Medulloblastoma; Biomarker; SELDI-TOF MS; Proteomics; 髄液

Medulloblastoma is a highly malignant pediatric brain tumor with a strong tendency for widespread cerebrospinal dissemination, which is the main cause of death. The identification of specific biomarkers for medulloblastoma would have great potential for improving the early detection of dissemination and evaluating the therapeutic effect. Recently, ProteinChip' technology has been developed to facilitate the protein pro filing of biological mixtures. Here we have applied this technology to identify potential biomarkers of medulloblastoma contained in the cerebral spinal fluids (CSF) of medulloblastoma patients. CSF samples were analyzed by ProteinChip technology using NP-1, H4 and SAX-2 chips. Subsequently, we attempted to identify the biomarker candidates by matching their molecular weights to known proteins in the several protein databases. Several biomarker candidates were identified, of which two proteins (15.3 and 16.0 kDa) were detected not only in the CSF but also in tissue lysate prepared from the medulloblastoma. The specificities and the sensitivities of the candidate biomarkers ranged from 66.7 to 100 % and from 87 to 100 %, respectively. Taken together, our results support the potential of this proteomic approach in the development of a highly sensitive diagnostic test for medulloblastoma.

髓母细胞瘤是一种高度恶性的小儿脑肿瘤，具有广泛的脑脊髓扩散的强烈趋势，这是死亡的主要原因。髓母细胞瘤特异性生物标志物的鉴定对于提高早期发现播散和评估治疗效果具有巨大潜力。最近，蛋白质芯片技术已经发展到促进生物混合物的蛋白质分析。在这里，我们已经应用这项技术来确定髓母细胞瘤患者的脑脊液（CSF）中所含的髓母细胞瘤的潜在生物标志物。采用NP-1、H4和SAX-2蛋白质芯片技术分析CSF样本。随后，我们试图通过将其分子量与几个蛋白质数据库中的已知蛋白质进行匹配来鉴定生物标志物候选物。几个生物标志物的候选人进行了鉴定，其中两个蛋白质（15.3和16.0 kDa）不仅在CSF中，但也从髓母细胞瘤制备的组织裂解液中检测到。候选生物标志物的特异性和灵敏度范围分别为66.7%至100%和87%至100%。总之，我们的研究结果支持这种蛋白质组学方法在开发成神经管细胞瘤高灵敏度诊断测试中的潜力。

项目成果

古田誠, 白石哲也, 上田茂雄, 鈴山堅志, 田渕和雄, 深瀬優, 有國 尚: "SELDI-TOF mass spectrometry (ProteinChip)を利用した髄芽腫の髄液バイオマーカー同定の試み"神経免疫研究. 13. 61-65 (2000)

Makoto Furuta、Tetsuya Shiraishi、Shigeo Ueda、Kenji Suzuyama、Kazuo Tabuchi、Masaru Fukase、Hisashi Arikuni：“尝试使用 SELDI-TOF 质谱法（蛋白质芯片）识别髓母细胞瘤的脑脊液生物标志物” Neuroimmune Research 13. 61-65 (2000) ）

吉田誠, 白石哲也, 上田茂雄, 鈴山堅志, 田渕和雄: "ポストシークエンス時代の脳腫瘍の研究と治療"九州大学出版会(印刷中). 500 (2000)

吉田诚、白石哲也、上田繁雄、铃山健二、田渊一夫：“后序列时代脑肿瘤的研究与治疗”九州大学出版社（正在出版）500（2000）。

Furuta K, Shiraishi T, Suzuyama K, Ueda S, Okamoto H, Tabuchi K: "Protein profiling in cerebrospinal fluid using Protein Chip SELDI-TOF mass spectrometry and biomarker discovery of medulloblastoma"Proceedings of 10^<th> annual meeting of Japan society for

Furuta K、Shiraishi T、Suzuyama K、Ueda S、Okamoto H、Tabuchi K：“使用蛋白质芯片 SELDI-TOF 质谱分析脑脊液中的蛋白质分析和髓母细胞瘤的生物标志物发现”日本学会第 10 届年会论文集

田渕和雄, 白石哲也: "アポトーシスからみたグリオーマの病態と治療"脳神経外科AdvancedPractice. 5. 154-159 (2001)

Kazuo Tabuchi、Tetsuya Shiraishi：“从细胞凋亡角度观察神经胶质瘤的病理学和治疗”《神经外科高级实践》5. 154-159 (2001)。

Furuta, K., Shiraishi, T., Ueda, S., Suzuyama, K., Tabuchi, K., Fukase, Y., Arikuni, H.: "Identification of medullooblastoma biomarker in cerebrospinal fluids by SELDI-TOF mass spectrometry"Neuroimmunology. 13. 61-65 (2000)

Furuta, K.、Shiraishi, T.、Ueda, S.、Suzuyama, K.、Tabuchi, K.、Fukase, Y.、Arikuni, H.：“通过 SELDI-TOF 质谱法鉴定脑脊液中的髓母细胞瘤生物标志物”